Virus-Like Particles Market Scope and Key Players Analysis by 2028
Virus-Like Particles Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 4.6 Billion |
Market Size by 2028 | US$ 7.86 Billion |
Global CAGR (2021 - 2028) | 7.9% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Product Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Virus-Like Particles (VLPs) Market – by Product Type
- Hepatitis
- Cancer/HPV
- Gaucher Disease
Virus-Like Particles (VLPs) Market – by Source
- Yeast
- Insect Cell
- Plant
- Others
Virus-Like Particles (VLPs) Market – by Application
- Vaccines
- Therapeutics
Virus-Like Particles (VLPs) Market – by Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.